Prof. Jörg Bojunga - Leiter Schwerpunkt Endokrinologie, Diabetologie, Ernährungsmedizin des Universitätsklinikum Frankfurt Goethe-Universität - erläutert ausgehend von der Nationalen VersorgungsLeitlinie (NVL) Typ-2-Diabetes die optimale medikamentöse antihyperglykämische Therapie für Patienten mit Diabetes Mellitus Typ 2.
2:02 Orale Antidiabetika (Metformin, DPP-IV Inhibitoren, SGLT-2 Inhibitoren, Sulfanylharnstoffe)
14:29 Insulin / Insulinanaloga
24:24 Inkretinmimetika / Tirzapetid
Das Gespräch wurde am 08.02.2022 geführt. Moderatoren: Prof. Dr. Marcus Säemann (Wien), Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern / Homburg) und Prof. Dr. Gunnar Heine (Frankfurt am Main / Homburg).
Diskutierte Studien:
Cosentino F et al.; ESC Scientific Document Group.
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Eur Heart J. 2020 doi: 10.1093/eurheartj/ehz486
Gaede P, Pedersen O.
Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis.
Diabetes. 2004 doi: 10.2337/diabetes.53.suppl_3.s39.
Schernthaner G, Chilton RJ.
Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
Diabetes Obes Metab. 2010 doi: 10.1111/j.1463-1326.2010.01262.x.
ADVANCE Collaborative Group
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med. 2008 doi: 10.1056/NEJMoa0802987
Wang Q, Shi M.
Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis.
Anticancer Drugs. 2022 doi: 10.1097/CAD.0000000000001254.
Dormandy JA et al., PROactive Investigators.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet. 2005 doi: 10.1016/S0140-6736(05)67528-9.
Zhang P et al.
Association of metformin use with cancer incidence and mortality: a meta-analysis.
Cancer Epidemiol. 2013 doi: 10.1016/j.canep.2012.12.009
Eibl G, Rozengurt E.
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.
Cancer Metastasis Rev. 2021 doi: 10.1007/s10555-021-09977-z.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Teilpublikation der Langfassung, 2. Auflage. Version 1. 2021 DOI: 10.6101/AZQ/000475. www.leitlinien.de/diabetes
Zhang Z et al.
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Cardiovasc Diabetol. 2017 doi: 10.1186/s12933-017-0512-z.
Anker et al.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction Anker et al., New England Journal of Medicine 2021 Empagliflozin in Heart Failure with a Preserved Ejection Fraction
New England Journal of Medicine 2021
https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
Positionspapier der DDG zur Therapie des DM im Krankenhaus
Stellungnahmen der Deutschen Diabetes Gesellschaft
05.08.2018
https://www.deutsche-diabetes-gesellschaft.de/politik/stellungnahmen/krankenhaus
Hensen J et al.
Management of diabetes mellitus and hospital-related hyperglycemia in patients of a medical ICU, with the use of two "down-to-earth" protocols: a feasibility study.
Exp Clin Endocrinol Diabetes. 2007 doi: 10.1055/s-2007-980177.
ORIGIN Trial Investigators, Gerstein HC et al.
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N Engl J Med. 2012 doi: 10.1056/NEJMoa1203858
Dahl D et al.
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
JAMA. 2022 doi: 10.1001/jama.2022.0078.
Kernan WN et al.; IRIS Trial Investigators.
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
N Engl J Med. 2016 doi: 10.1056/NEJMoa1506930
2.396 Lượt nghe
Video
